Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04627428 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
A Phase 1 study of Dry Age-Related Macular Degeneration, sponsored by Luxa Biotechnology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT04627428 is a Phase 1 study of Dry Age-Related Macular Degeneration that is actively recruiting participants, run by Luxa Biotechnology. The registered enrollment target is 18 participants, below the 81-participant average among 7 other Dry Age-Related Macular Degeneration trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04627428, a Phase 1 study of Dry Age-Related Macular Degeneration, is actively recruiting participants, sponsored by Luxa Biotechnology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
Conditions Studied
Interventions
- BIOLOGICAL RPESC-RPE-4W
Study Locations (3)
California
- Retina Vitreous Associates Medical Group - Beverly Hills
- Spencer Center for Vision Research - Palo Alto
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04627428
The ClinicalTrials.gov registry entry for NCT04627428 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 81-participant average among 7 other Dry Age-Related Macular Degeneration trials with a reported enrollment target (78% lower). The listed sponsor is Luxa Biotechnology, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Age-Related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which RPESC-RPE-4W is the first listed.
NCT04627428 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Michigan.
Frequently Asked Questions
What is clinical trial NCT04627428 about?
NCT04627428 is a clinical study titled "Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)". The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
What is the current status of trial NCT04627428?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-04-05. Estimated completion is 2026-12-01.
What conditions does trial NCT04627428 study?
This clinical trial studies the following conditions: Dry Age-Related Macular Degeneration.
What interventions are being tested in trial NCT04627428?
The interventions under investigation include: RPESC-RPE-4W (BIOLOGICAL).
Who is sponsoring clinical trial NCT04627428?
This trial is sponsored by Luxa Biotechnology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04627428 being conducted?
This trial has 3 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Age-Related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
ACTIVE NOT RECRUITING · Phase 2
-
PRIMA US-Feasibility Study in Atrophic Dry AMD
ACTIVE NOT RECRUITING · NA
-
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
ACTIVE NOT RECRUITING
-
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.